Kura Oncology, Inc.
KURA
Positions held
Your positionsKURA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kura Oncology is positioned in a competitive biotechnology sector with a strong focus on innovative cancer therapies, which can attract significant investor interest.
- The company has shown a revenue growth of 36.5% year-over-year, indicating strong demand for its products.
- In the latest quarter, Kura reported a revenue increase of 14% compared to the previous quarter, reaching $21 million.
- The biotechnology industry is highly regulated, and Kura faces challenges in navigating these regulations, which can impact its growth trajectory.
- Kura's operating margin is currently at -349.8%, reflecting significant operational losses.
- The company's score indicates a 'Strong Sell' signal with a score of -16.00, suggesting negative market sentiment.
Fundamentals
| Market cap | $935.87M | Enterprise value | $441.30M | Trailing P/E | — | Forward P/E | -4.48 |
| PEG | — | Price / book | 19.34 | Beta | 0.47 | Dividend yield | 0.00% |
| Revenue growth | 36.5% | Earnings growth | — | Gross margin | -2.4% | Operating margin | -3.5% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -31.3% | Debt / equity | 0.50 |
| Current ratio | 4.73 | Free cash flow | -$165.88M | Analyst recommendation | strong_buy | Mean target | $31.85 |
| 52w high | $13.90 | 52w low | $7.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $20.9M | $18.3M | $17.3M | $20.8M | $15.3M | — |
| Op margin | -349.8% | -431.5% | -497.6% | -385.5% | -475.3% | — |
| Net income | -$68.3M | -$73.3M | -$81.0M | -$74.1M | -$66.1M | — |
| Gross margin | 98.8% | 98.6% | — | — | 100.0% | — |
| Gross profit | $20.6M | $18.0M | — | — | $15.3M | $14.1M |
| Operating income | -$73.0M | -$78.8M | -$86.3M | -$80.0M | -$72.7M | — |
- Revenue +14% vs prior quarter ($21M vs $18M).
- Gross margin 98.8% (was 98.6% prior quarter).
- Operating margin expanded to -349.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0.0M | $0.0M |
| Op margin | -449.9% | -358.5% | — | — |
| Net income | -$279M | -$174M | -$153M | -$136M |
| Gross margin | 99.9% | 100.0% | — | — |
| Gross profit | $67.4M | $53.9M | $0.0M | — |
| Operating income | -$304M | -$193M | -$166M | -$140M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
2026-10-01 · JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target
2026-09-29 · Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
2026-09-09 · Kura spins diabetes work into a Lilly-backed biotech startup
2026-09-09 · Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
2026-09-09 · Kura Oncology Launches Caspian Therapeutics With $50 Million Funding
2026-09-08 · Kura Oncology Names Jennifer Fulk Finance Chief
2026-09-08 · Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
2026-09-04 · Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns